AZNCF Healthcare
AstraZeneca PLC
| P/E Trailing | -- |
| P/E Forward | -- |
| PEG Ratio | -- |
| Market Cap | -- |
| Price Target | -- |
| D/E Ratio | -- |
| Current Ratio | -- |
| Cash | -- |
| Total Debt | -- |
| Net Cash | -- |
| Gross Margin | -- |
| Operating Margin | -- |
| Net Margin | -- |
| ROE | -- |
| FCF | -- |
| GF Score | -- |
| Altman Z-Score | -- |
| Piotroski F-Score | -- |
| Div. Yield | -- |
| Analyst Rating | -- |
STRONG SELL: Metrics within normal ranges.
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the …
IRWD expects Linzess demand to accelerate, driving a bullish 2026 outlook with revenue growth, higher profits and expanding adoption.
AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.
Shell’s chief executive is on course to become one of the best-paid executives on the London Stock Exchange as his company’s move away from green energy pays off.
AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete response letter.
The FDA has accepted and granted Priority Review for DATROWAY, co-developed by AstraZeneca (LSE:AZN) and Daiichi Sankyo, as a first-line treatment for certain patients with metastatic triple-negative breast cancer. The …
The latest trading day saw Astrazeneca (AZN) settling at $184.32, representing a -2.17% change from its previous close.
Highly rated drugmaker AstraZeneca got an IBD SmartSelect Composite Rating upgrade to 96 Tuesday, up from 92 the day before. The Composite Rating upgrade comes a day after AstraZeneca's stock …
US regulator issues complete response letter on self-administered Saphnelo as Astra works to resubmit application.
AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are thinking of selling their position in the stock for …